HER2 regulated miRNA expression in letrozole resistant breast cancer

被引：4
|
作者：
Kazi, Armina A. [1 ]
Sabnis, Gauri [1 ]
Zhou, Qun [1 ]
Chumsri, Saranya [1 ]
Schech, Amanda [1 ]
Shah, Preeti [1 ]
Brodie, Angela [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1471
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1471
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Trastuzumab targeting of HER2 upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2 positive breast cancer
    Le, Xiao-Feng
    Wu, Yun
    Spizzo, Riccardo
    Yoo, Suk-Young
    Wang, Jing
    Calin, George A.
    Bast, Robert C.
    CANCER RESEARCH, 2011, 71
  • [42] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [43] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
  • [44] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [45] Comparison of HER2 expression status between conventional HER2 test and VENTANA HER2 (4B5) of metastatic breast cancer
    Tokudome, N.
    Sugino, T.
    Nishimura, S.
    Bekku, E.
    Hayashi, T.
    Tadokoro, Y.
    Takahashi, K.
    Nakashima, K.
    Uematsu, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1336 - S1337
  • [46] Computational pathology based HER2 expression quantification in HER2-low breast cancer
    Spitzmueller, Andreas
    Kapil, Ansh
    Shumilov, Anatoliy
    Chan, Jessica
    Konstantinidou, Lemonia
    Hassan, Zonera
    Gustavson, Mark
    Carroll, Danielle
    Della Varghese
    James, Gareth D.
    Moh, Akira
    Livingston, Andrew
    de Giorgio-Miller, Victoria
    CANCER RESEARCH, 2023, 83 (05)
  • [47] miR-489 function as tumor suppressor miRNA by targeting HER2 in HER2-positive breast cancer
    Patel, Yogin
    Shah, Nirav
    Botbyl, Racheal
    Lee, Jishin
    Chen, Hexin
    CANCER RESEARCH, 2015, 75
  • [48] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [49] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [50] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
12345